Mulholland, Ryan J. http://orcid.org/0009-0008-7250-7464
Ciminata, Giorgio
Quinn, Terry J.
Pollock, Kevin G.
Lister, Steven
Geue, Claudia
Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer UK
Article History
Accepted: 14 July 2024
First Online: 2 August 2024
Declarations
:
: This study was sponsored by Pfizer and Bristol Myers Squibb. Employees of the respective funding bodies were involved in the design of the study, writing of the manuscript, and decision-making regarding publication of the manuscript.
: RM, GC, TQ, and CG have received research grants from Bristol Myers Squibb and Pfizer UK. TQ is a data monitoring committee chair for Novo Nordisk. KP was previously employed by Bristol Myers Squibb. SL was previously employed by Bristol Myers Squibb and owns stocks and shares in Pfizer and Bristol Myers Squibb.
: The proposal for this study was approved by the University of Glasgow Medicine, Veterinary Medicine and Life Sciences (MVLS) College Ethics Committee, although ethical approval is not required for the analysis of secondary Scottish administrative health data. It was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements.
: The data utilised in the study is confidential, and analyses were subject to disclosure control by PHS. Data access can be requested by application to PHS via the Public Benefit and Privacy Panel.
: All authors made substantial contributions to study conception and design. Material preparation, data collection and analysis were performed by RM, GC, and CG. The first draft of the manuscript was written by RM, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.